Skip to main content

Phase 1/2 Neurology Deal Benchmarks

Median Upfront
$223M
Range: $101M - $351M
Total Deal Value
$2.3B
Range: $1.3B - $3.4B
Royalty Rate
9.9% - 17.3%
Tiered up to 21.3%
Dev Milestones
$885M
Range: $496M - $1.3B

Market Analysis

Phase 1/2 neurology licensing deals carry a median total deal value of $2.3B, with upfront payments ranging from $101M to $351M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 10% to upfront and 90% to milestones.

The neurology landscape at the phase 1/2 stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $885M, regulatory milestones contribute $695M, and commercial milestones reach $527M. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.

Royalty rates for phase 1/2 neurology deals range from 9.9% to 17.3% at the base tier, with high-tier escalation to 21.3%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 1/2 neurology deals?
Phase 1/2 neurology deals average $223M in upfront payments, ranging from $101M to $351M. The upfront allocation of 10% of total deal value reflects the clinical stage risk profile.
How are phase 1/2 neurology deal milestones structured?
Milestones account for approximately 90% of total deal value. Development milestones ($885M) represent the largest component, followed by commercial milestones ($527M) and regulatory milestones ($695M).
What royalty rates are typical for phase 1/2 neurology licensing?
Base royalty rates range from 9.9% to 17.3%, with tiered escalation to 13.9%-21.3% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included